Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia

New England Journal of Medicine

Volumn 314, Issue 12, 1986, Pages 729-735

  Storb, Rainer ^a   Deeg, H Joachim ^a   Whitehead, John ^a   Appelbaum, Frederick ^a   Beatty, Patrick ^a   Bensinger, William ^a   Buckner, C Dean ^a   Clift, Reginald ^a   Doney, Kristine ^a   Farewell, Vernon ^a   Hansen, John ^a   Hill, Roger ^a   Lum, Lawrence ^a   Martin, Paul ^a   Mcguffin, Robert ^a   Sanders, Jean ^a   Stewart, Patricia ^a   Sullivan, Keith ^a   Witherspoon, Robert ^a   Yee, Gary ^a   Thomas, E Donnall ^a   more..

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBALT 60; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; FOLINATE CALCIUM; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; ADVERSE DRUG REACTION; BLOOD AND HEMOPOIETIC SYSTEM; BONE MARROW TRANSPLANTATION; CARDIOVASCULAR SYSTEM; DRUG COMPARISON; DRUG THERAPY; GRAFT VERSUS HOST REACTION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTOXICATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LEUKEMIA; MAJOR CLINICAL STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; THERAPY;

EID: 0022624255     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198603203141201     Document Type: Article

References (43)

1. Thomas ED, Buckner CD, Clift RA, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 1979; 301: 597–9.
2. Forman SJ, Spruce WE, Farbstein MJ, et al. Bone marrow ablation followed by allogeneic marrow grafting during first complete remission of acute nonlymphocytic leukemia. Blood 1983; 61: 439–42.
3. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclo-phosphamide. N Engl J Med 1983; 309: 1347–53.
4. Gale RP, Kay HEM, Rimm AA, Bortin MM. Bone-marrow transplantation for acute leukaemia in first remission. Lancet 1982; 2: 1006–9.
5. Powles RL, Clink HM, Spence D, et al. Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation. Lancet 1980; 1: 327–9.
6. Deeg HJ, Storb R, Thomas ED, et al. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 1985; 65: 1325–34.
7. Clift RA, Buckner CD, Thomas ED, et al. The treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation. Lancet 1982; 2: 621–3.
8. J.M., Goldman, J.F., Apperley, R.E., Marcus, et al., Bone marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia: apparent low incidence of relapse within the first two years post-BMT, Exp Hematol, (1985), 13, 14-15
9. Speck B, Bortin MM, Champlin R, et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1984; 1: 665–8.
10. Champlin R, Ho W, Arenson E, Gale RP. Allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic or accelerated phase. Blood 1982; 60: 1038–41.
11. Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med (in press).
12. Storb R, Deeg HJ, Thomas ED, et al. Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood 1985; 66: 698–702.
13. Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 1981; 2: 327–31.
14. Filipovich AH, McGlave PB, Ramsay NKC, Goldstein G, Warkentin PI, Kersey JH. Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histo-compatible bone-marrow transplantation. Lancet 1982; 1: 1266–9.
15. Prentice HG, Blacklock HA, Janossy G, et al. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia. Lancet 1982; 1: 700–3.
16. Mitsuyasu RT, Champlin RE, Ho WG, et al. Prevention of graft-versus-host disease (GVHD) by ex vivo treatment of donor bone marrow with monoclonal anti-T cell antibody (CT-2) and complement: results of a prospective randomized controlled trial. Blood 1984; 64: 218a. abstract.
17. Prentice HG, Blacklock HA, Janossy G, et al. Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet 1984; 1: 472–6.
18. Martin PJ, Hansen JA, Buckner CD, et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985; 66: 664–72.
19. Irle C, Deeg HJ, Buckner CD, et al. Marrow transplantation for leukemia following fractionated total body irradiation: a comparative trial of methotrexate and cyclosporine. Leuk Res 1985; 9: 1255–61.
20. H.J., Deeg, R., Storb, P.L., Weiden, et al., Cyclosporin A and methotrexate in canine marrow transplantation: engraftment, graft-versus-host disease, and induction of tolerance, Transplantation, (1982), 34, 30-35
21. H.J., Deeg, R., Storb, F.R., Appelbaum, M.S., Kennedy, T.C., Graham, E.D., Thomas, Combined immunosuppression with cyclosporine and methotrexate in dogs given bone marrow grafts from DLA-haploidentical littermates, Transplantation, (1984), 37, 62-65
22. Clift RA, Buckner CD, Thomas ED, et al. Allogeneic marrow transplantation using fractionated total body irradiation in patients with acute lymphoblastic leukemia in relapse. Leuk Res 1982; 6: 401–7.
23. Freedman LS, White SJ. On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics 1976; 32: 691–4.
24. Yee GC, Kennedy MS, Storb R, Thomas ED. Effect of hepatic dysfunction on oral cyclosporine pharmacokinetics in marrow transplant patients. Blood 1984; 64: 1277–9.
25. Buckner CD, Clift RA, Sanders JE, et al. Protective environment for marrow transplant recipients. Ann Intern Med 1978; 89: 893–901.
26. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 832–43, 895–902.
27. Doney KC, Weiden PL, Storb R, Thomas ED. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. Am J Hematol 1981; 11: 1–8.
28. Storb R, Gluckman E, Thomas ED, et al. Treatment of established human graft-versus-host disease by antithymocyte globulin. Blood 1974; 44: 57–75.
29. Remlinger K, Martin PJ, Hansen JA, et al. Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease. Hum Immunol 1984; 9: 21–35.
30. Whitehead J. The design and analysis of sequential clinical trials. Chichester, England: Horwood, 1983.
31. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187–202.
32. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
33. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81.
34. Loughran TP Jr, Deeg HJ, Dahlberg S, Kennedy MS, Storb R, Thomas ED. Incidence of hypertension after marrow transplantation among 112 patients randomized to either cyclosporine or methotrexate as graft-versus-host disease prophylaxis. Br J Haematol 1985; 59: 547–53.
35. Deeg HJ, Storb R, Weiden PL, Graham T, Atkinson K, Thomas ED. Cyclosporin A: effect on marrow engraftment and graft-versus-host disease in dogs. Transplant Proc 1981; 13: 402–4.
36. Ramsay NKC, Kersey JH, Robison LL, et al. A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 1982; 306: 392–7.
37. Weiden PL, Floumoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068–73.
38. Weiden PL, Sullivan KM, Floumoy N, Storb R, Thomas ED. Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529–33.
39. Sanders JE, Floumoy N, Thomas ED, et al. Marrow transplant experience in children with acute lymphoblastic leukemia: an analysis of factors associated with survival, relapse and graft-versus-host disease. Med Pediatr Oncol 1985; 13: 165–72.
40. Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings: beneficial effect of a protective environment. N Engl J Med 1983; 308: 302–7.
41. Navari RM, Buckner CD, Clift RA, et al. Prophylaxis of infection in patients with aplastic anemia receiving allogeneic marrow transplants. Am J Med 1984; 76: 564–72.
42. Kennedy MS, Yee GC, Deeg HJ, Storb R, Thomas ED. Pharmacokinetics and toxicity of cyclosporine in marrow transplant patients. Transplant Proc 1983; 15: 2416–8.
43. Kennedy MS, Deeg HJ, Siegel M, Crowley JJ, Storb R, Thomas ED. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation 1983; 35: 211–5.